Immunoprecipitation News and Research

RSS

New application note describes ChIP assay technology for screening multiple epigenetic targets

Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation assay technology.

From Chromatrap® - Porvair Sciences Ltd 16 Jul 2013

RORA: A novel candidate gene for autism regulates large number of other genes

A new study by Valerie Hu, Ph.D., professor of biochemistry and molecular medicine at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), reports that RORA, a novel candidate gene for autism discovered by her group in a 2010 study, regulates a large number of other genes associated with autism.

2 Jul 2013

Virginia Tech's Chang Lu awarded new NIH grant to research on cancer

Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.

11 Jun 2013

Chromatrap® ChIP assay kit enriches epigenetic marks from primary human tissue cells

A new application note from Porvair Sciences details a protocol for its Chromatrap® ChIP assay kit that has been developed to enrich epigenetic marks from primary human tissue cells.

From Chromatrap® - Porvair Sciences Ltd 28 May 2013

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.

From Chromatrap® - Porvair Sciences Ltd 28 Mar 2013

Researchers create high-resolution map of gene regulatory elements in the brain

Future research into the underlying causes of neurological disorders such as autism, epilepsy and schizophrenia, should greatly benefit from a first-of-its-kind atlas of gene-enhancers in the cerebrum (telencephalon).

2 Feb 2013

GeneTex to introduce new EasyBlot reagent

GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that they will be launching EasyBlot, a new secondary antibody reagent that eliminates the interference that has long plagued immunoprecipitation (IP) experiments when the IP and western blot primary antibodies are from the same host.

16 Jan 2013

Brake for skin inflammation discovered

The absence of a protein called Ctip2 in the skin allows increased levels of T-helper 2 cytokines and may have a role in conditions such as atopic dermatitis, research in mice suggests.

4 Jan 2013

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Parental methylated histones not transferred to daughter DNA

It's widely accepted that molecular mechanisms mediating epigenetics include DNA methylation and histone modifications, but a team from Thomas Jefferson University has evidence to the contrary regarding the role of histone modifications.

24 Aug 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

30 May 2012

PRDM16 transcription co-factor plays a critical role in development of embryonic palate

In the United States, a baby is born with a facial cleft every hour, of every day of the year! Such birth defects result from both gene mutations and environmental insults. PRDM16 is a transcription factor originally described as being aberrantly activated in specific types of leukemia's, and more recently as a master regulator of brown adipose tissue differentiation.

3 May 2012

Insight into relationship between two types of suppressors in cancerous tumors

The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.

23 Feb 2012

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

An alternative solid phase affinity matrix for chromatin immunoprecipitation

Porvair Filtration Group working in collaboration with the Department of Biological Sciences, University of Essex, UK has produced an alternative, high performance Solid Phase Affinity Matrix for Chromatin Immunoprecipitation (ChIP) assays. The research at Essex University evaluating the new BioVyon - Protein A material in ChIP assays is published in the May 2011 issue of Analytical Biochemistry.

From Chromatrap® - Porvair Sciences Ltd 23 May 2011